Evercore ISI lowered the firm’s price target on Thermo Fisher (TMO) to $575 from $650 and keeps an Outperform rating on the shares, which were also added to the firm’s “Tactical Outperform” as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Citi, Meta among ‘Top 10 US Ideas for Q2’ at BofA
- Thermo Fisher initiated with a Buy at DZ Bank
- Thermo Fisher Scientific: Early Clario Close Enhances 2026 Growth Outlook and AI-Driven Competitive Position, Supporting Buy Rating
- Thermo Fisher Completes Strategic Acquisition of Clario Holdings
- Thermo Fisher completes acquisition of Clario Holdings for $8.875B in cash